The Italian Journal of Neurological Sciences

, Volume 5, Issue 3, pp 289–293

Effectiveness of Bornaprine on parkinsonian tremor

  • Sancesario G. 
  • Cicardi M. C. 
  • Fiermonte G. 
  • Giacomini P. 
  • Stanzione P. 
Original Articles

Abstract

The effectiveness of Bornaprine on parkinsonian tremor was evaluated in a single-blind study of mediumterm treatment. 25 patients were treated with rising doses of Bornaprine per os, one week at each dose-level. The dose at which Bornaprine was most effective was 8 mg daily and its action at this dose was mild but statistically significant. The drug was generally well tolerated in patients with idiopathic parkinsonism, but transient confusion developed in a few patients with secondary parkinsonism.

Key-words

Parkinsonian tremor Bornaprine anticholinergic agent tremor suppressant action 

Sommario

Gli Autori hanno valutato in uno studio a singolo cieco l'efficacia della Bornaprine, sul tremore parkinsoniano durante un trattamento a medio termine.

Il farmaco è stato somministrato per os a dosi crescenti da 6 a 16 mg/die ad un gruppo di 25 pazienti.

La Bornaprine è stata generalmente ben tollerata in 18 dei pazienti affetti da Parkinson idiopatico mentre nei 7 pazienti affetti da parkinsonismo arteriosclerotico si è notata la frequente comparsa di transitori sintomi confusionali. L'attività tremorolitica del farmaco è apparsa modesta ma statisticamente significativa.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    AscherP.W.:Das anticholinergische Behandlungsprinzip des Morbus Parkinson. Wien Klin Wschr 88: 641–646, 1976.PubMedGoogle Scholar
  2. [2]
    Avernarius H.J., Gerstenbrand F.:Kr 339, ein neues tremorhemmendes Präparat zur Behandlung des Parkinson Syndroms. Wien Klin Wschr 80: 460–462, 1968.PubMedGoogle Scholar
  3. [3]
    Camarda R.,Bonavita V.A proposito della terapia del tremore Parkinsoniano. Atti della seconda riunione della Lega Italiana per la lotta contro il Morbo di Parkinson e le Malattie Extrapiramidali. Agnoli A., Bertolani G. (eds) 156–163, 1975.Google Scholar
  4. [4]
    Gangleberger J.A. et al.:Vergleichende neurophysiologische Untersuchungen tremorwirksamer Substanzen. Med Klin 60, 1283–1288, 1965.PubMedGoogle Scholar
  5. [5]
    Hoehn M.N. andYahr M.D.:Parkinsonism: Onset progression and mortality. Neurology 17: 427–422, 1976.Google Scholar
  6. [6]
    Iivanainen M.:Kr 339 in the treatment of Parkinsonian tremor. Acta Neurol. Scandinav. 50: 469–477, 1974.Google Scholar
  7. [7]
    Jankovic J., Frost J.D. In:Quantitative assessment of Parkinsonian and essential tremor: Clinical application of triaxial accelerometry. Neurology 31: 1235–1240, 1981.PubMedGoogle Scholar

Copyright information

© Masson Italia Periodici S.r.l. 1984

Authors and Affiliations

  • Sancesario G. 
    • 1
  • Cicardi M. C. 
    • 1
  • Fiermonte G. 
    • 1
  • Giacomini P. 
    • 1
  • Stanzione P. 
    • 1
  1. 1.II Clinica delle Malattie Nervose e Mentali Università degli Studi di Roma “La Sapienza”Italia

Personalised recommendations